New World Evidence Data Market
New World Evidence Data Market Overview
The report is titled ‘New World Evidence Data Market: Opportunity Analysis and Future Assessment 2020-2028’. An overview of conceptual frameworks, analytical approaches of the new world evidence data market is the main objective of the report, which further consists of the market opportunity and insights of the data involved in the making of the respective market. The new world evidence data market is expected to grow at a significant rate in the near future.
The global new world evidence data market in 2020 is estimated for more than US$ 883.5 Bn and expected to reach a value of US$ 2,607.4 Bn by 2028 with a significant CAGR of 14.6%.
New World Evidence Data Market Definition
Basically, real-world data (RWD) can be defined as the data which is regularly compiled from different sources associated with a consignment of healthcare and patient health conditions. By the same token, real-world evidence (RWE) may be defined as the clinical evidence about the pharmaceutical product acquired for evaluation of real-world data along with its usage, potential advantages, or hazards.
In addition to that, there has been a huge chunk of health-related data to gather and store, and this data is stored in various kinds of devices such as biosensors, computers, mobile devices, smart wearable, and many more.
Although notably, the huge chunk of healthcare data is of great importance as it gives answers to many questions in the healthcare setting which were previously infeasible as well as it helps in new clinical trials and drug development processes.
Along with that, the real-world evidence data also helps in the development of new pharmaceutical products and their approval as the data can be analyzed and the results of the analysis can be applied in the development process. Owing to this, the global new world evidence data market is projected to boost rapidly in the near future.
New World Evidence Data Market Dynamics
The growing usage of the electronic health record systems as an observational system for the patient is primarily flourishing the global new world evidence data market. For instance, according to Health IT Buzz, in September 2016, in the United States, nearly 96% of hospitals and 78% of doctors use certified electronic health record systems.
In addition to that, the constantly growing need for enhanced medical products and devices and increasing count of novel clinical trials for the approval of new drug products is further projected to fuel the growth of the new world evidence data market in the near future. Along with that, there is a rising trend of targeted therapies as well as the development of new and improved treatments, which is also estimated to lead to the rapid growth of the new world evidence market during the forecast period.
Other than that, the huge shift in the modern-day world, from volume-based data to value-based data is also acting as a major driver that is expected to further propel the growth of the global new world evidence data market in the near future. Attributing to all such factors, the new world evidence data market is anticipated to witness significant growth in the coming years.
Further, the use of new clinical trials for the approval of the drugs has also thrived the target market. In addition, the development of new treatment and targeted therapies have also led to the growth of the global new world evidence data market. Moreover, the use of the social media platforms to share the new therapies and data has also evolved the target market. Furthermore, moving from volume-based data to value-based data has also helped to grow the global new world evidence data market.
New World Evidence Data Market Segmentation
By Component:
Dataset (Claims, Clinical, Pharmacy, Patient),
Services
By Therapeutic Area:
Oncology
Cardiovascular
Immunology
By End User:
Pharmaceuticals
Medical Devices
Payers
Providers
By Region:
North America
Europe
Asia Pacific
Latin America
Middle East
Africa
New World Evidence Data Market for the Use of New Clinical Trial Overview
Many years of consistent research and development is done by pharmaceutical companies to introduce new drug or molecule in the market. For which pharmaceutical companies invest a huge amount of money from their revenue in research and development in which the probability of getting a positive results is very low. Owing to companies mainly in pharmaceutical and biotech, the usage of Real-world evidence (RWE) insights which are very useful for life-cycle management and for the development of drugs is growing at a rapid rate which increases the expenditure on clinical trials and innovation. Presently, the usage of a clinical-genomic database with tumor sequencing information for targeted drug development and cancer discovery studies is done by big pharmaceutical companies.
New World Evidence Data Market Competitive Landscape
Some of the key participating players in the global new world evidence data market are Oracle, IQVIA, International Business Machines Corporation, Syneos Health, ICON, Pharmaceutical Product Development, Optum, Cognizant, SAS, and Flatiron Health.
MMC Overview on New World Evidence Data Market Report
The non-identical approach of Meridian Market Consultants stands with conceptual methods backed up with the data analysis. The novel market understanding approach makes up the standard of the assessment results that give a better opportunity for the customers to put their effort.
A research report on the New World Evidence Data market by Meridian Market Consultants is an in-depth and extensive study of the market based on the necessary data crunching and statistical analysis. It provides a brief view of the dynamics flowing through the market, which includes the factors that support the market and the factors that are acting as impedance for the growth of the market.
Furthermore, the report includes the various trends and opportunities in the respective market in different regions for a better understanding of readers that helps to analyze the potential of the market.
Factors that are benchmarked while estimating the market
Various factors that are benchmarked while estimating the market growth include (but not restricted to):
• New product designs and launches
• Current product compliance
• Reimbursement
• Concerns for use of New World Evidence Data
• Advantages of New World Evidence Data
Actions taken by the manufacturer and respective regulatory authorities also impact the market growth of the segment. These factors are understood at a regional level and in major countries globally for providing regional insights into the product segment in the report. This helps our clients to make an informed decision.
A mix of top-down and bottom-up approach is followed to arrive at and validate our market value estimations. For a product segment like wherein one/two manufacturer(s) dominates the market, its product sales, previous growth rates, and market expansion plans are considered to generate market share in the global market.
1. Global New World Evidence Data Market Report Overview
1.1. Introduction
1.2. Report Description
1.3. Methodology
2. Global New World Evidence Data Market Overview
2.1. Introduction
2.1.1. Market Definition
2.1.2. Market Taxonomy
2.2. Executive Summary
2.3. Global New World Evidence Data Market Snapshot
2.4. Global New World Evidence Data Market Size and Forecast, 2020–2028
2.4.1. Introduction
2.4.2. Market Value Forecast and Annual Growth Rate (AGR) Comparison (2020–2028)
2.5. Global New World Evidence Data Market Dynamics
2.5.1. Drivers
2.5.2. Restraints
2.5.3. Opportunity
2.5.4. Trends
2.6. Key Regulations
2.7. Porter’s Five Forces Model
3. Global New World Evidence Data Market, By Components
3.1. Introduction
3.1.1. Annual Growth Rate Comparison, By Components
3.1.2. BPS Analysis, By Components
3.2. Market Revenue (US$Mn) Forecast, By Components
3.2.1. Dataset (Claims, Clinical, Pharmacy, Patient),
3.2.2. Services
3.3. Global New World Evidence Data Market Attractiveness Index, By Components
4. Global New World Evidence Data Market, By Therapeutic Area
4.1. Introduction
4.1.1. Annual Growth Rate Comparison, By Therapeutic Area
4.1.2. BPS Analysis, By Therapeutic Area
4.2. Market Revenue (US$Mn) Forecast, By Therapeutic Area
4.2.1. Oncology
4.2.2. Cardiovascular
4.2.3. Immunology
4.3. Global New World Evidence Data Market Attractiveness Index, By Therapeutic Area
5. Global New World Evidence Data Market, By End User
5.1. Introduction
5.1.1. Annual Growth Rate Comparison, By End User
5.1.2. BPS Analysis, By End User
5.2. Market Revenue (US$Mn) Forecast, By End User
5.2.1. Pharmaceuticals
5.2.2. Medical Devices
5.2.3. Payers
5.2.4. Providers
5.3. Global New World Evidence Data Market Attractiveness Index, By End User
6. Global New World Evidence Data Market, By Region
6.1. Introduction
6.1.1. Annual Growth Rate Comparison, By Region
6.1.2. BPS Analysis, By Region
6.2. Market Revenue (US$Mn) Forecast, By Region
6.2.1. North America
6.2.2. Latin America
6.2.3. Europe
6.2.4. Asia Pacific
6.2.5. Middle East
6.2.6. Africa
6.3. Global New World Evidence Data Market Attractiveness Index, By Region
7. North America New World Evidence Data Market Analysis and Forecast, 2020–2028
7.1. Introduction
7.1.1. Annual Growth Rate Comparison, By Country
7.1.2. BPS Analysis, By Country
7.2. Market Revenue (US$Mn) Forecast, By Country
7.2.1. U.S. New World Evidence Data Market
7.2.2. Canada New World Evidence Data Market
7.3. North America New World Evidence Data Market, By Components
7.3.1. Dataset (Claims, Clinical, Pharmacy, Patient),
7.3.2. Services
7.4. North America New World Evidence Data Market, By Therapeutic Area
7.4.1. Oncology
7.4.2. Cardiovascular
7.4.3. Immunology
7.5. North America New World Evidence Data Market, By End User
7.5.1. Pharmaceuticals
7.5.2. Medical Devices
7.5.3. Payers
7.5.4. Providers
7.6. North America New World Evidence Data Market Attractiveness Index
7.6.1. By Country
7.6.2. By Components
7.6.3. By Therapeutic Area
7.6.4. By End User
8. Latin America New World Evidence Data Market Analysis and Forecast, 2020–2028
8.1. Introduction
8.1.1. Annual Growth Rate Comparison, By Country
8.1.2. BPS Analysis, By Country
8.2. Market (US$Mn) Forecast, By Country
8.2.1. Brazil New World Evidence Data Market
8.2.2. Mexico New World Evidence Data Market
8.2.3. Argentina New World Evidence Data Market
8.2.4. Rest of Latin America New World Evidence Data Market
8.3. Latin America New World Evidence Data Market, By Components
8.3.1. Dataset (Claims, Clinical, Pharmacy, Patient),
8.3.2. Services
8.4. Latin America New World Evidence Data Market, By Therapeutic Area
8.4.1. Oncology
8.4.2. Cardiovascular
8.4.3. Immunology
8.5. Latin America New World Evidence Data Market, By End User
8.5.1. Pharmaceuticals
8.5.2. Medical Devices
8.5.3. Payers
8.5.4. Providers
8.6. Latin America New World Evidence Data Market Attractiveness Index
8.6.1. By Country
8.6.2. By Components
8.6.3. By Therapeutic Area
8.6.4. By End User
9. Europe New World Evidence Data Market Analysis and Forecast, 2020–2028
9.1. Introduction
9.1.1. Annual Growth Rate Comparison, By Country
9.1.2. BPS Analysis, By Country
9.2. Market (US$Mn) Forecast, By Country
9.2.1. U.K. New World Evidence Data Market
9.2.2. Germany New World Evidence Data Market
9.2.3. Italy New World Evidence Data Market
9.2.4. France New World Evidence Data Market
9.2.5. Spain New World Evidence Data Market
9.2.6. Russia New World Evidence Data Market
9.2.7. Poland New World Evidence Data Market
9.2.8. BENELUX New World Evidence Data Market
9.2.9. NORDIC New World Evidence Data Market
9.2.10. Rest of Europe New World Evidence Data Market
9.3. Europe New World Evidence Data Market, By Components
9.3.1. Dataset (Claims, Clinical, Pharmacy, Patient),
9.3.2. Services
9.4. Europe New World Evidence Data Market, By Therapeutic Area
9.4.1. Oncology
9.4.2. Cardiovascular
9.4.3. Immunology
9.5. Europe New World Evidence Data Market, By End User
9.5.1. Pharmaceuticals
9.5.2. Medical Devices
9.5.3. Payers
9.5.4. Providers
9.6. Europe New World Evidence Data Market Attractiveness Index
9.6.1. By Country
9.6.2. By Components
9.6.3. By Therapeutic Area
9.6.4. By End User
10. Asia Pacific New World Evidence Data Market Analysis and Forecast, 2020–2028
10.1. Introduction
10.1.1. Annual Growth Rate Comparison, By Country
10.1.2. BPS Analysis, By Country
10.2. Market (US$Mn) Forecast, By Country
10.2.1. China New World Evidence Data Market
10.2.2. India New World Evidence Data Market
10.2.3. Japan New World Evidence Data Market
10.2.4. Australia and New Zealand New World Evidence Data Market
10.2.5. South Korea New World Evidence Data Market
10.2.6. ASEAN New World Evidence Data Market
10.2.7. Rest of Asia Pacific New World Evidence Data Market
10.3. Asia Pacific New World Evidence Data Market, By Components
10.3.1. Dataset (Claims, Clinical, Pharmacy, Patient),
10.3.2. Services
10.4. Asia Pacific New World Evidence Data Market, By Therapeutic Area
10.4.1. Oncology
10.4.2. Cardiovascular
10.4.3. Immunology
10.5. Asia Pacific New World Evidence Data Market, By End User
10.5.1. Pharmaceuticals
10.5.2. Medical Devices
10.5.3. Payers
10.5.4. Providers
10.6. Asia Pacific New World Evidence Data Market Attractiveness Index
10.6.1. By Country
10.6.2. By Components
10.6.3. By Therapeutic Area
10.6.4. By End User
11. Middle East New World Evidence Data Market, By Region
11.1. Introduction
11.1.1. Annual Growth Rate Comparison, By Country
11.1.2. BPS Analysis, By Country
11.2. Market (US$Mn) Forecast, By Country
11.2.1. GCC Countries New World Evidence Data Market
11.2.2. Israel New World Evidence Data Market
11.2.3. Oman New World Evidence Data Market
11.2.4. Rest of Middle East New World Evidence Data Market
11.3. Middle East New World Evidence Data Market, By Components
11.3.1. Dataset (Claims, Clinical, Pharmacy, Patient),
11.3.2. Services
11.4. Middle East New World Evidence Data Market, By Therapeutic Area
11.4.1. Oncology
11.4.2. Cardiovascular
11.4.3. Immunology
11.5. Middle East New World Evidence Data Market, By End User
11.5.1. Pharmaceuticals
11.5.2. Medical Devices
11.5.3. Payers
11.5.4. Providers
11.6. Middle East New World Evidence Data Market Attractiveness Index
11.6.1. By Country
11.6.2. By Components
11.6.3. By Therapeutic Area
11.6.4. By End User
12. Africa New World Evidence Data Market, By Region
12.1. Introduction
12.1.1. Annual Growth Rate Comparison, By Country
12.1.2. BPS Analysis, By Country
12.2. Market (US$Mn) Forecast, By Country
12.2.1. South Africa New World Evidence Data Market
12.2.2. Egypt New World Evidence Data Market
12.2.3. North Africa New World Evidence Data Market
12.2.4. Rest of Africa New World Evidence Data Market
12.3. Africa New World Evidence Data Market, By Components
12.3.1. Dataset (Claims, Clinical, Pharmacy, Patient),
12.3.2. Services
12.4. Africa New World Evidence Data Market, By Therapeutic Area
12.4.1. Oncology
12.4.2. Cardiovascular
12.4.3. Immunology
12.5. Africa New World Evidence Data Market, By End User
12.5.1. Pharmaceuticals
12.5.2. Medical Devices
12.5.3. Payers
12.5.4. Providers
12.6. Africa New World Evidence Data Market Attractiveness Index
12.6.1. By Country
12.6.2. By Components
12.6.3. By Therapeutic Area
12.6.4. By End User
13. Recommendation
13.1. Market Strategy
14. Competitive Landscape
14.1. Competition Dashboard
14.2. List and Company Overview of Global Key Players
14.3. Company Profiles
14.3.1. Oracle
14.3.1.1. Company Overview
14.3.1.2. Financial Overview
14.3.1.3. Component Portfolio
14.3.1.4. Key Developments
14.3.1.5. Business Strategies
14.3.2. IQVIA
14.3.3. International Business Machines Corporation
14.3.4. Syneos Health
14.3.5. ICON
14.3.6. Pharmaceutical Product Development
14.3.7. Optum
14.3.8. Cognizant
14.3.9. SAS
14.3.10. Flatiron Health
15. Acronyms